MedTrace Logo

Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers

NCT02452996 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-10-20

No results posted yet for this study

Summary

In this clinical study, the safety and tolerability of GNbAC1 as a treatment for MS patients will be evaluated in healthy male volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

GNbAC1

Single dose of IMP, IV infusion

Sponsors & Collaborators

  • GeNeuro Innovation SAS

    lead INDUSTRY

Principal Investigators

  • Georg Golor, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452996 on ClinicalTrials.gov